Harnessing the power of four scientific disciplines, Starpax Biopharma Inc., a biopharmaceutical research and development company, has conceived a revolutionary platform technology to treat cancer.

Previous Amounts Raised: $60 million
Founder: Michel Gareau
Year Founded: 2017

Reg A+ offering made available through Starpax Biopharma. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. Please see the most recent Offering Circular for more information.

Benzinga may receive monetary compensation from the issuer, or its agency, for publicizing the offering of the issuer’s securities. This content is for informational purposes only and is not intended to be investing advice. This is a paid ad.

This Biotech's Never Before Seen Magnetodrones Technology Could Revolutionize Cancer Treatment

Michael Gareau, Chairman of the Board, Founding President & CEO of Starpax Biopharma, was recently interviewed by Benzinga.

Starpax is a biopharma and medtech company that has developed an innovative platform for treating cancer. The company has developed what it calls Magnetodrones, which deliver cancer drugs directly into a tumor. They are self-propelled and do not need to enter the bloodstream. They work in tandem with the Polartrak, a device that keeps the Magnetodrones contained within the tumor.

The company is currently seeking FDA approval for six indications with unmet needs.

Watch the full interview here:

Featured photo by Louis Reed on Unsplash.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechInterviewGeneralStarpax Biopharma
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!